Clinical Trial Update: Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating tipifarnib as postconsolidation therapy for acute myeloid leukemia in patients aged …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tipifarnib (Zarnestra) (tipifarnib)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED